BR112014003096A2 - uso de ccne2 como marcador de estratificação no tratamento de tumores de mama com inibidores de pan-cdk - Google Patents

uso de ccne2 como marcador de estratificação no tratamento de tumores de mama com inibidores de pan-cdk

Info

Publication number
BR112014003096A2
BR112014003096A2 BR112014003096A BR112014003096A BR112014003096A2 BR 112014003096 A2 BR112014003096 A2 BR 112014003096A2 BR 112014003096 A BR112014003096 A BR 112014003096A BR 112014003096 A BR112014003096 A BR 112014003096A BR 112014003096 A2 BR112014003096 A2 BR 112014003096A2
Authority
BR
Brazil
Prior art keywords
ccne2
treatment
pan
breast tumors
cdk inhibitors
Prior art date
Application number
BR112014003096A
Other languages
English (en)
Inventor
Siemeister Gerhard
Groth Philip
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of BR112014003096A2 publication Critical patent/BR112014003096A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)

Abstract

resumo patente de invenção: "uso de ccne2 como marcador de estratificação no tratamento de tumores de mama com inibidores de pan-cdk". a invenção refere-se ao uso de ccne2 como marcadores de estratificação no tratamento de tumores de mama com novos inibidores de pan-cdk da fórmula (i). (i). 20452304v1 1/1 20452304v1
BR112014003096A 2011-08-16 2012-08-15 uso de ccne2 como marcador de estratificação no tratamento de tumores de mama com inibidores de pan-cdk BR112014003096A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011080991A DE102011080991A1 (de) 2011-08-16 2011-08-16 Verwendung von CCNE2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
PCT/EP2012/065947 WO2013024118A1 (de) 2011-08-16 2012-08-15 Verwendung von ccne2 als stratifikationsmarker bei der behandlung von brusttumoren mit neuen pan-cdk-inhibitoren

Publications (1)

Publication Number Publication Date
BR112014003096A2 true BR112014003096A2 (pt) 2017-02-21

Family

ID=46963669

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014003096A BR112014003096A2 (pt) 2011-08-16 2012-08-15 uso de ccne2 como marcador de estratificação no tratamento de tumores de mama com inibidores de pan-cdk

Country Status (13)

Country Link
US (1) US20140221243A1 (pt)
EP (1) EP2744915A1 (pt)
JP (1) JP2014524250A (pt)
KR (1) KR20140044911A (pt)
CN (1) CN103732762A (pt)
AU (1) AU2012296839A1 (pt)
BR (1) BR112014003096A2 (pt)
CA (1) CA2845324A1 (pt)
DE (1) DE102011080991A1 (pt)
EA (1) EA201490411A1 (pt)
IL (1) IL230781A0 (pt)
MX (1) MX2014001810A (pt)
WO (1) WO2013024118A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011080992A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von MAD2L2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902887B1 (en) * 1999-03-22 2005-06-07 Novozymes Biotech, Inc. Methods for monitoring multiple gene expression
EP1717232A1 (de) * 2005-04-28 2006-11-02 Bayer CropScience GmbH Phenylsulfonylharnstoffe mit herbizider Wirkung
EP1803723A1 (de) * 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
DE102006027156A1 (de) * 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
DE102006041382A1 (de) * 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
EP1939185A1 (de) * 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs
ITBO20080429A1 (it) * 2008-07-08 2010-01-09 Paolo Amadesi Impianto per la riduzione dell'anidride carbonica contenuta nei fumi di combustione.
JP2012506238A (ja) * 2008-10-20 2012-03-15 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト インスリン様増殖因子−１受容体キナーゼ阻害剤に対する抗がん反応を予測する生物学的マーカー
EP2179991A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
EA201490411A1 (ru) 2014-07-30
US20140221243A1 (en) 2014-08-07
CA2845324A1 (en) 2013-02-21
EP2744915A1 (de) 2014-06-25
IL230781A0 (en) 2014-03-31
CN103732762A (zh) 2014-04-16
MX2014001810A (es) 2014-03-31
AU2012296839A1 (en) 2014-02-27
DE102011080991A1 (de) 2013-02-21
WO2013024118A1 (de) 2013-02-21
JP2014524250A (ja) 2014-09-22
KR20140044911A (ko) 2014-04-15

Similar Documents

Publication Publication Date Title
BR112014013526A8 (pt) conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
NZ626618A (en) Hydroxamic acid derivatives and uses thereof
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
AR091837A1 (es) Compuestos para inmunoterapia dirigida
BR112014013108A2 (pt) compostos tricíclicos fundidos como inibidores da quinase raf
BR112013019028A2 (pt) derivados de 7-azaindol
EA201400579A1 (ru) Антитела к il-36r
EA201400178A1 (ru) Лечение рака молочной железы
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
CR20150271A (es) Peptidos como agonistas de oxitocina
BR112014003096A2 (pt) uso de ccne2 como marcador de estratificação no tratamento de tumores de mama com inibidores de pan-cdk
MX343160B (es) Dicetopiperazinas para uso en inhibir hiperpermeabilidad vascular.
UY34117A (es) Derivados de polimixina útiles como agentes antibacterianos
CR20150245A (es) Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer
UY32987A (es) Nuevo uso antitumoral de cabazitaxel
MX2019010875A (es) Derivados de uncialamicina, metodos de sintesis y su uso como agentes antitumor.
BR112013008711A2 (pt) "bomba de mama"
IN2014DN09228A (pt)
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
IN2014DN06104A (pt)
BR112015029504A2 (pt) inibidores quinase
TR201903918T4 (tr) Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
MX2015014470A (es) Analogos de combretastatina.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]